<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177668</url>
  </required_header>
  <id_info>
    <org_study_id>YS1101</org_study_id>
    <nct_id>NCT03177668</nct_id>
  </id_info>
  <brief_title>Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110
      intravenous administration in patients with malignant pleural mesothelioma and to
      preliminarily examine the anti-tumor effect of YS110.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Status of onset of Dose Limiting Toxicity (DLT)</measure>
    <time_frame>18 days</time_frame>
    <description>Assessed by number of subjects with DLT of YS110</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects with assessed overall response as Complete Response (CR), Partial Response (PR) or Stable Disease (SD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Assessed for duration of study participation which is estimated to be 18 months</time_frame>
    <description>The period from the starting day of the administration to Progressive Disease (PD) or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Assessed for duration of study participation which is estimated to be 18 months</time_frame>
    <description>The proportion of subjects with assessed the best overall response as CR or PR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed for duration of study participation which is estimated to be 18 months</time_frame>
    <description>The period from the starting day of the administration to death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LCSS-Meso</measure>
    <time_frame>Assessed for duration of study participation which is estimated to be 18 months</time_frame>
    <description>Assessed for Quality of life (QOL) by using the modified Lung Cancer Symptom Scale for mesothelioma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>Assessed for duration of study participation which is estimated to be 18 months</time_frame>
    <description>Assessed for QOL by using the Japanese versions of EORTC QLQ-C30 in the cancer patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>YS110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 part: Administration of 3 different dose cohort
Phase 2 part: Administration of recommended dose determined from result of Phase 1 part</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YS110</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>YS110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with male or female aged â‰¥ 20 (and aged &lt; 75 in Phase 1 part)

          -  Patients whose malignant pleural mesothelioma was histologically confirmed

          -  Patients who have advanced pleural mesothelioma that are refractory to existing
             anti-tumor drugs and who have no other standard therapies which should be prioritized

          -  Patients whose most recent major surgery (except exploratory thoracotomy or
             laparotomy) or drug or radiation therapy for malignant tumors, if any, was at least 4
             weeks ago (at least 12 weeks ago for immunotherapy) at the subject enrollment

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 1 or less

        Exclusion Criteria:

          -  Patients whose toxicity findings in the previous treatment (antineoplastic agents)
             have not been yet restored

          -  Patients with tumor lesions in central nervous system confirmed in MRI or CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuo Kanai</last_name>
    <role>Study Director</role>
    <affiliation>Kissei Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kissei Pharmaceutical Co., Ltd</last_name>
    <phone>(Email only)</phone>
    <email>rinsyousiken@pharm.kissei.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo and Other Japanese Cities</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

